P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1564
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV